Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

The health sector had 21 companies reporting their quarterly earnings this week, with 18 of them beating profit estimates for the quarter. Quarter-To-Date, The Health Care Select Sector SPDR Fund ETF ...

Your local pharmacy might be the next front in Donald Trump’s trade war. The president has in recent weeks promised to impose tariffs on all foreign-made medications, a move intended to encourage drug ...

Mounjaro brought in $3.5 billion in the period, while Zepbound added $1.9 billion to the tally, showing an advance on the $3.1 billion and $1.3 billion reported with the drugs in the third quarter ...

which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved, as reported earlier this month. Under US law, compounding pharmacies can make and sell patent ...

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.